• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 08, 2022 at 12:12: AM
via Many Gilead Sciences investors have lost faith in Trodelvy in HR-positive, HER2-negative breast cancer after disappointing data on tumor progression. But the antibody-drug conjugate has now made a surprise comeback with a life extension benefit that's greater than industry watchers’ expectations, reigniting blockbuster hopes.

article source
 




Top Bottom
Back
Quote